Resveratrol Ameliorates the Oxidative Damage Induced by Arsenic Trioxide in the Feline Lung

Cheng, Yanyan; Xue, Jianming; Yao, Chunyu; Li, Gao; Ma, Deying; Liu, Yan; Zhang, Zhigang

doi:10.1292/jvms.13-0004

Cited by 7 publications

(3 citation statements)

References 43 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CS exposure was carried out (five cigarettes for five times a day (one cigarette/time) with 30‐min smoke‐free interval for 3 consecutive days) by burning a commercially available filter cigarette (White Shark brand, Tobacco Company, People's Republic of China) according to manufacturer's specification (1 mg nicotine/cigarette; 13 mg tar/cigarette) . Oral administration of resveratrol (1 or 3 mg/kg) or vehicle (1% DMSO in 0.1 mL phosphate buffered saline (PBS)) was given 1 h before CS treatment . Mice were anesthetized with Avertin (2,2,2‐tribromoethanol, 250 mg/kg ip; Sigma‐Aldrich, St. Louis, MO) and euthanized by exsanguination.…”

Section: Methodsmentioning

confidence: 99%

Resveratrol Protects against Cigarette Smoke–Induced Oxidative Damage and Pulmonary Inflammation

Liu

Ren

Chen

et al. 2014

J Biochem & Molecular Tox

View full text Add to dashboard Cite

This study was carried out to investigate the effects of resveratrol on cigarette smoke (CS)-induced lung injury. Experimental mice were administrated with 1 mg/kg or 3 mg/ kg resveratrol orally, 1 h prior to CS exposure (five cigarettes a day for 3 consecutive days). Airway inflammation and gene expression changes were assessed. CS exposure increased the number of pulmonary inflammatory cells, coupled with elevated production of tumor necrosis factor α and interleukin-6 in bronchoalveolar lavage fluids. Resveratrol treatment decreased CS-induced lung inflammation. Resveratrol restored the activities of superoxide dismutase, GSH peroxidase, and catalase in CS-treated mice. CS significantly enhanced the nuclear translocation of nuclear factor κB (NF-κB) and NF-κB DNA binding activity, which was impaired by resveratrol pretreatment. In addition, resveratrol promoted CS-induced heme oxygenase-1 (HO-1) expression and activation. Our results collectively indicate that resveratrol attenuates CS-induced lung oxidative injury, which involves decreased NF-κB activity and the elevated HO-1 expression and activity.

show abstract

Section: Methodsmentioning

confidence: 99%

Resveratrol Protects against Cigarette Smoke–Induced Oxidative Damage and Pulmonary Inflammation

Liu

Ren

Chen

et al. 2014

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…In guinea pig ventricular cardiomyocytes, resveratrol ameliorated arsenic trioxide-induced damage of the human ether-a-go-go-related gene (hERG) current, relieved endoplasmic reticulum stress, and shortened the action potential duration [171]. Resveratrol also had a protective effect against arsenic trioxide-induced oxidative damage in the feline brain, lung, and kidney [172,173,174], and nephrotoxicity and hepatotoxicity in rats [175,176].…”

Section: Other Cardiotoxic Cancer Treatmentsmentioning

confidence: 99%

Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology

2019

View full text Add to dashboard Cite

Cardio-oncology is a clinical/scientific discipline which aims to prevent and/or treat cardiovascular diseases in cancer patients. Although a large number of cancer treatments are known to cause cardiovascular toxicity, they are still widely used because they are highly effective. Unfortunately, therapeutic interventions to prevent and/or treat cancer treatment-induced cardiovascular toxicity have not been established yet. A major challenge for such interventions is to protect the cardiovascular system without compromising the therapeutic benefit of anticancer medications. Intriguingly, the polyphenolic natural compound resveratrol and its analogs have been shown in preclinical studies to protect against cancer treatment-induced cardiovascular toxicity. They have also been shown to possess significant anticancer properties on their own, and to enhance the anticancer effect of other cancer treatments. Thus, they hold significant promise to protect the cardiovascular system and fight the cancer at the same time. In this review, we will discuss the current knowledge regarding the cardio-protective and the anticancer properties of resveratrol and its analogs. Thereafter, we will discuss the challenges that face the clinical application of these agents. To conclude, we will highlight important gaps of knowledge and future research directions to accelerate the translation of these exciting preclinical findings to cancer patient care.

show abstract

“…Histopathological examination of the kidneys and bladder revealed minor inflammatory infiltrates, but these were not considered significant (Johnson et al., ). Another study in cats reported a protective effect against reactive oxygen species in cats with pulmonary exposure to arsenic (Cheng et al., ). However, to date, the authors are unaware of any metabolism and safety studies published in cats.…”

Section: Introductionmentioning

confidence: 99%

Lack of glucuronidation products of trans‐resveratrol in plasma and urine of cats

Burnett

Puschner

Ramsey

et al. 2016

Animal Physiology Nutrition

View full text Add to dashboard Cite

Resveratrol has generated interest in cats due to reported health benefits. Cats have low activity of β-glucuronidase, and we hypothesized they could not form two common resveratrol metabolites, resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide. Resveratrol, 3 mg/cat/day, was given orally to intact male (n = 5) and female cats (n = 5) for 4 weeks. A control group (8 intact males) was used for comparison. Plasma and urine were collected weekly and analysed using high-pressure liquid chromatography coupled with tandem mass spectrometry. Resveratrol and resveratrol-3-O-sulphate, but no glucuronide metabolites, were detected in plasma and urine. Median (range 10-90th percentile) plasma resveratrol for control and treatment groups was 0.46 ng/ml (0.02-1.74 ng/ml) and 0.96 ng/ml (0.65-3.21 ng/ml). Median (range) plasma resveratrol-3-O-sulphate for control and treatment groups was 6.32 ng/ml (2.55-10.29 ng/ml) and 11.45 ng/ml (1.47-53.29 ng/ml). Plasma resveratrol differed from control in week 4, while plasma resveratrol-3-O-sulphate was different in all weeks (p < 0.05). Median (range) urine resveratrol for control and treatment groups was 0.28 ng/ml (0.05-1.59 ng/ml) and 19.98 ng/ml (8.44-87.54 ng/ml). Median (range) urine resveratrol-3-O-sulphate for control and treatment groups was 26.71 ng/ml (10.50-75.58 ng/ml) and 108.69 ng/ml (11.83-231.05 ng/ml). All time points for urine resveratrol and resveratrol-3-O-sulphate were significantly different from control (p < 0.05), except for weeks 1, 3 and 4 for resveratrol. The results support our hypothesis that cats are unlikely able to glucuronidate resveratrol, most likely due to a reduction in the activity of β-glucuronidase.

show abstract

Resveratrol Ameliorates the Oxidative Damage Induced by Arsenic Trioxide in the Feline Lung

Cited by 7 publications

References 43 publications

Resveratrol Protects against Cigarette Smoke–Induced Oxidative Damage and Pulmonary Inflammation

Resveratrol Protects against Cigarette Smoke–Induced Oxidative Damage and Pulmonary Inflammation

Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology

Lack of glucuronidation products of trans‐resveratrol in plasma and urine of cats

Contact Info

Product

Resources

About